Status:
UNKNOWN
The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients
Lead Sponsor:
Oslo University Hospital
Conditions:
SARS-CoV Infection
COVID 19
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The (World Health Organization) WHO NOR- (Coronavirus infectious disease) COVID 19 study is a multi-centre, adaptive, randomized, open clinical trial to evaluate the safety and efficacy of hydroxychlo...
Eligibility Criteria
Inclusion
- Adult patients, 18 years and above
- Confirmed SARS-2-CoV-2 infection by PCR
- Admitted to the hospital ward or the ICU
- Subjects (or legally authorized representative) provides written informed consent prior to initiation of the study
Exclusion
- Severe co-morbidity with life expectancy \<3 months according to investigators assessment
- (Aspartate Transaminase/ Alanine Aminotransferase) ASAT/ALAT \> 5 times the upper limit of normal
- Acute co-morbidity within 7 days before inclusion such as myocardial infarction
- Known intolerance to the available study drugs
- Pregnancy, possible pregnancy or breast feeding
- Any reason why, in the opinion of the investigators, the patient should not participate
- Subject participates in a potentially confounding drug or device trial during the course of the study
- Prolonged QT interval (\>450 ms)
Key Trial Info
Start Date :
March 28 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2020
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT04321616
Start Date
March 28 2020
End Date
November 1 2020
Last Update
April 14 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Andreas Barratt-Due
Oslo, Norway, 0756